OncLive TV

Sundar Jagannath, MBBS, discusses the mechanism of action and tolerability of linvoseltamab in patients with relapsed/refractory multiple myeloma.

Omid Hamid, MD, discusses how lifileucel may address historical unmet needs in relapsed melanoma.

Christina L. Roland, MD, MS, FACS, discusses a study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma.

Ashish Saxena, MD, PhD, discusses recent shifts in treatment with the use of targeted and immune therapies in non–small cell lung cancer.

Shruti Tiwari, MD, discusses treatment sequencing in HER2+ breast cancer, highlighting how to treat these patients when they present with CNS involvement.

Scott Kopetz, MD, PhD, FACP, discusses the clinical efficacy and safety of adagrasib plus cetuximab in patients with KRAS G12C-mutated mCRC.

Katharina Hoebel, MD, PhD discusses the efficacy of incorporating spatial interactions within predictive models, in the realm of oncology.

Catherine C. Coombs, MD, discusses strategies for disease classification and management for patients with acute myeloid leukemia.

Naomi Adjei, MD, MPH, MSEd, discusses an analysis of the cost-effectiveness of opportunistic salpingectomy for the primary prevention of ovarian cancer.

John M. Kirkwood, MD, discusses the significance of the FDA approval of adjuvant nivolumab for patients with resected stage IIB or IIC melanoma.

Nizar M. Tannir, MD, FACP, discusses unmet needs for patients with rare kidney tumors and how these needs may be addressed in the future.

William B. Pearse, MD, discusses the current treatment paradigm for patients with relapsed/refractory mantle cell lymphoma.

Daniel Olson, MD, discusses toxicities associated with lifileucel and IL-2 in patients with unresectable or metastatic melanoma.

Nan Chen, MD, discusses the investigation of CDK4/6 inhibitors in early-stage breast cancer.

Robert Dreicer, MD, discusses different approaches in prostate cancer management according to the type of oncologist.

Akriti Jain, MD, discusses updated data from the phase 3 MEDALIST trial evaluating luspatercept for the treatment of anemic myelodysplastic syndromes.

Samer A. Srour, MB ChB, MS, discusses toxicities associated with CTX130 in advanced clear cell renal cell carcinoma.

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the phase 3 ATHENA-MONO trial in newly diagnosed patients with advanced ovarian cancer.

Julia Foldi, MD, PhD, discusses the evolving role of treatment with T-DXd in metastatic HER2-positive breast cancer.

Carmen Guerra MD, MSCE, examines how a culturally sensitive could help raise prostate cancer screening awareness.

Kara Maxwell, MD, PhD discusses a study of genetic testing results in metastatic prostate cancer.

Abdulrahman Sinno, MD, discusses the shift in focus to molecular characteristics of endometrial cancer.

Margaret E. Gatti-Mays, MD, MPH, FACP, discusses the current use of neoadjuvant chemoimmunotherapy in early-stage triple-negative breast cancer.

Erin K. Crane, MD, MPH, discusses the impact of the phase 3 PRIMA trial on second-line maintenance approaches in ovarian cancer.

Omid Hamid, MD on adoptive T cell therapy, lifileucel, for patients with patients with advanced melanoma.

Eric Vallieres, MD, FRCSC, discusses the impact of induction therapy on surgical candidacy and operative complexity in patients with thoracic malignancies.

Josep Maria Piulats Rodriguez, MD, discusses an analysis evaluating predictive biomarkers for treatment with talazoparib plus enzalutamide in mCRPC.

Samer A. Srour, MB ChB, MS, discusses the utility of the CAR T-cell therapy CTX130 and unmet needs in advanced clear cell renal cell carcinoma.

William B. Pearse, MD, discusses the current role of the BTK inhibitor pirtobrutinib in patients with relapsed/refractory mantle cell lymphoma.

Núria Agustí Garcia, MD, discusses the MELISA trial, which is evaluating further steps toward lymphadenectomy replacement in ovarian cancer.